Glucose transporter proteins Inhibitors
1 drugsAbout Glucose transporter proteins
Glucose transporter proteins (GLUTs) facilitate glucose transport across cell membranes, maintaining glucose homeostasis and supplying energy to cells. These proteins are implicated in various physiological processes due to their crucial role in glucose metabolism.
While no genetic evidence directly links GLUTs to specific diseases, their importance in glucose metabolism makes them potential targets for drug development. Targeting GLUTs offers a potential avenue for therapeutic intervention in diseases with dysregulated glucose metabolism, such as cancer.
One FDA-approved drug, Fludeoxyglucose F18, targets glucose transporter proteins as a small molecule. This drug, marketed by PETNET, was first approved in 1994 and falls into the 'other' therapeutic area category.
Top Glucose transporter proteins Drugs
PETNET is the only company with an approved drug targeting glucose transporter proteins.
Low competition suggests a potential first-mover advantage for new entrants in this space.
Glucose transporter proteins Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Glucose transporter proteins, using small molecule modality.
The lack of diverse modalities represents a whitespace opportunity for novel biologics targeting GLUTs.
Glucose transporter proteins Clinical Trials 8 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Glucose transporter proteins. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 4 | 2 | 2 | 0 | 50% |
| Phase 2 | 4 | 3 | 0 | 1 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Glucose transporter proteins Drug Approval Timeline (1994 - 1994)
Evaluation of malignancy in patients with known or suspec...
The first and only drug targeting GLUTs was approved in 1994.
The lack of recent approvals indicates potential saturation or challenges in developing new GLUT-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 8 (0 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Glucose transporter proteins. A trial counts if an approved drug acting on Glucose transporter proteins is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.